Ad is loading...
SVFAX
Price
$84.12
Change
+$0.90 (+1.08%)
Updated
Nov 22 closing price
VVIAX
Price
$70.26
Change
+$0.54 (+0.77%)
Updated
Nov 22 closing price
Ad is loading...

SVFAX vs VVIAX

Header iconSVFAX vs VVIAX Comparison
Open Charts SVFAX vs VVIAXBanner chart's image
Smead Value A
Price$84.12
Change+$0.90 (+1.08%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$70.26
Change+$0.54 (+0.77%)
VolumeN/A
CapitalizationN/A
SVFAX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
SVFAX vs. VVIAX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SVFAX is a Buy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. SVFAX (6.28B). VVIAX pays higher dividends than SVFAX: VVIAX (2.36) vs SVFAX (1.27). SVFAX was incepted earlier than VVIAX: SVFAX (11 years) vs VVIAX (24 years). SVFAX is a more actively managed with annual turnover of: 15.60 vs. VVIAX (10.00). SVFAX (3000) and VVIAX (3000) have matching initial minimum investment requirements. VVIAX annual gain was more profitable for investors over the last year : 26.09 vs. SVFAX (23.06). SVFAX return over 5 years is better than : 70.45 vs. VVIAX (53.09).
SVFAXVVIAXSVFAX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence11 years24 years-
Gain YTD10.19619.67252%
Front LoadN/AN/A-
Min. Initial Investment30003000100%
Min. Initial Investment IRAN/AN/A-
Net Assets6.28B184B3%
Annual Yield % from dividends1.272.3654%
Returns for 1 year23.0626.0988%
Returns for 3 years18.1824.7773%
Returns for 5 years70.4553.09133%
Returns for 10 years117.85112.26105%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics